CV Sciences Files 2024 10-K
Ticker: CVSI · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1510964
| Field | Detail |
|---|---|
| Company | Cv Sciences, Inc. (CVSI) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, litigation
TL;DR
CV Sciences dropped its 2024 10-K. Check out their 2023 retained earnings and 2024 note payable.
AI Summary
CV Sciences, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as CannaVest Corp., operates in the Pharmaceutical Preparations sector. Key financial elements mentioned include Retained Earnings for 2023, Employee Stock Options for 2023, and a Cultured Foods Note Payable as of December 31, 2024.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of CV Sciences' financial performance and business operations for the fiscal year 2024, including details on liabilities and equity.
Risk Assessment
Risk Level: medium — The filing mentions pending litigation, which can introduce financial and operational risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-27 — Filing Date (The date the 10-K was submitted to the SEC.)
- 2023-12-31 — Retained Earnings Period (Reporting period for retained earnings.)
- 2023-12-31 — Employee Stock Option Period (Reporting period for employee stock options.)
- 2024-12-31 — Cultured Foods Note Payable (Indicates a note payable related to cultured foods as of year-end 2024.)
Key Players & Entities
- CV Sciences, Inc. (company) — Filer of the 10-K
- CannaVest Corp. (company) — Former name of CV Sciences, Inc.
- 2024-12-31 (date) — Fiscal year end and reporting period
- 2025-03-27 (date) — Filing date
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 0001510964 (company_id) — Central Index Key for CV Sciences, Inc.
- Otilda Lamont Litigation (litigation) — Specific pending litigation mentioned
FAQ
What was the total revenue for CV Sciences in fiscal year 2024?
The provided excerpt does not contain specific revenue figures for fiscal year 2024.
What is the nature of the 'Cultured Foods Note Payable' mentioned?
The excerpt indicates a 'Cultured Foods Note Payable' as of December 31, 2024, but does not provide details on its terms or purpose.
What is the status and potential impact of the 'Otilda Lamont Litigation'?
The filing notes 'Otilda Lamont Litigation' as 'Pending Litigation' as of December 31, 2023, but does not detail its potential financial impact.
What were the Selling, General, and Administrative Expenses for the fiscal year 2024?
The excerpt references 'SellingGeneralAndAdministrativeExpense' but does not provide the specific dollar amount for 2024.
What is the company's current market capitalization?
The provided text is an excerpt from a 10-K filing and does not include current market capitalization data.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding CV Sciences, Inc. (CVSI).